Kahn Brothers Group Inc. Acquires Shares of 464,001 Pfizer Inc. $PFE

Kahn Brothers Group Inc. acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 464,001 shares of the biopharmaceutical company’s stock, valued at approximately $11,173,000. Pfizer comprises approximately 0.0% of Kahn Brothers Group Inc.’s investment portfolio, making the stock its 26th biggest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Vermillion Wealth Management Inc. lifted its holdings in Pfizer by 19.4% during the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 382 shares during the last quarter. Eagle Capital Management LLC grew its stake in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 390 shares during the last quarter. Delta Financial Advisors LLC increased its holdings in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after buying an additional 398 shares in the last quarter. Pines Wealth Management LLC raised its stake in shares of Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 400 shares during the last quarter. Finally, Mount Vernon Associates Inc. MD raised its stake in shares of Pfizer by 1.0% in the first quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock valued at $1,177,000 after acquiring an additional 400 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research note on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.28.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Pfizer Stock Down 1.0%

Shares of NYSE PFE opened at $28.00 on Friday. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The firm’s 50-day moving average is $25.49 and its 200-day moving average is $26.29. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $159.62 billion, a PE ratio of 36.85 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the firm posted $0.78 earnings per share. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer’s dividend payout ratio is 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.